Re: Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

Journal of the National Cancer Institute

Volumn 104, Issue 14, 2012, Pages 1106-

  Gulley, James L ^a   Leitman, Susan F ^a   Dahut, William ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DEXAMETHASONE; DOCETAXEL; MITOXANTRONE; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SIPULEUCEL T; ZIBOTENTAN;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LETTER; LEUKAPHERESIS; MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

AGING; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; TISSUE EXTRACTS;

EID: 84864428172     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs280     Document Type: Letter

References (5)

1. H uber ML, Haynes L, Parker C, et al. Interdisciplinary critique of sipuleucel-T as immunotherapy in castrationresistant prostate cancer. J Natl Cancer Inst. 2012;104(4):273-279.
2. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
3. Kolf C, Bolan C, Wesley R, et al. Sustained decreases in lymphocyte counts in serial long-term leukapheresis donors. Transfusion. 2003;43(9s):28A.
4. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett. 2007;108(1):45-51.
5. M ark D, Samson D, Bonnell C, et al. Outcomes of sipuleucel-T therapy: Technology assessment report [online]. https://www.cms.gov/determinationprocess/ downloads/id77TA.pdf. Accessed January 25, 2012.